Mark Sulkowski, MD

CRS:

JHU

Role:

Investigators

Position:

Site Investigator

Email:

msulkows@jhmi.edu
  • Chair, Hepatitis TSG (Dec 2016)
  • Chair, Steering Committee of Hepatitis TSG (Dec 2016)
  • SC Representative, Scientific Agenda Steering Committee (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair 5329
  • Vice-Chair, 5360
  • Co-chair 5334s
  • Investigator, 5335s

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More